Active Ingredient(s): Tiludronate
FDA Approved: * March 7, 1997
Pharm Company: * SANOFI AVENTIS US
Category: Paget's Disease

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Skelid Overview

Tiludronic acid (INN; also known as tiludronate) is a bisphosphonate used for treatment of Paget's disease of bone (osteitis deformans) in human medicine. It has the tradename Skelid. In veterinary medicine, tiludronic acid is used to treat navicular disease and bone spavin in horses. Its tradenames are Tildren and Equidronate. It is approved for treatment of navicular disease and distal tarsal osteoarthritis in Europe,[1] and was approved for treatment of navicular disease i...

Read more Skelid Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Skelid Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 200mg, 240mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Skelid: (1 result)

Sorted by National Drug Code
  • 0024-1800 Skelid 200 mg (As Tiludronate Disodium 240 mg) Oral Tablet by Sanofi-aventis U.S. LLC

Other drugs which contain Tiludronate or a similar ingredient: (1 result)